HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >

Randomized Trial of Effect of Urate-Lowering Agent Febuxostat in Chronic Heart Failure Patients with Hyperuricemia (LEAF-CHF)

Files in This Item:

The file(s) associated with this item can be obtained from the following URL:https://doi.org/10.1536/ihj.17-560


Title: Randomized Trial of Effect of Urate-Lowering Agent Febuxostat in Chronic Heart Failure Patients with Hyperuricemia (LEAF-CHF)
Authors: Yokota, Takashi Browse this author →KAKEN DB
Fukushima, Arata Browse this author →KAKEN DB
Kinugawa, Shintaro Browse this author →KAKEN DB
Okumura, Takahiro Browse this author
Murohara, Toyoaki Browse this author →KAKEN DB
Tsutsui, Hiroyuki Browse this author →KAKEN DB
Keywords: BNP
Oxidative stress
Xanthine oxidase inhibitor
Issue Date: 1-Sep-2018
Publisher: International Heart Journal Association
Journal Title: International Heart Journal
Volume: 59
Issue: 5
Start Page: 976
End Page: 982
Publisher DOI: 10.1536/ihj.17-560
Abstract: Hyperuricemia is an independent predictor of mortality in patients with chronic heart failure. The aim of the study is to determine whether a urate-lowering agent febuxostat, an inhibitor of xanthine oxidase, may improve the clinical outcomes in chronic heart failure patients with hyperuricemia when compared to conventional treatment. This multicenter, prospective, randomized, open-label, blinded endpoint study with a follow-up period of 24 weeks will enroll 200 Japanese chronic heart failure patients with hyperuricemia. The eligibility criteria include a diagnosis of chronic heart failure (New York Heart Association functional class II-III with a history of hospitalization due to worsening of heart failure within the last 2 years), reduced left ventricular systolic function (left ventricular ejection fraction < 40%) and increased plasma natriuretic peptide [plasma B-type natriuretic peptide (BNP) ? 100 pg/mL or N-terminal pro BNP (NT-proBNP) ? 400 pg/mL], and hyperuricemia (serum uric acid >7.0 mg/dL and ? 10 mg/dL) at the screening visit. The primary outcome is the difference in the plasma BNP levels between the baseline and 24 weeks of treatment. The plasma BNP levels are measured in the central laboratory in a blinded manner. This study investigates the efficacy and safety of febuxostat in chronic heart failure patients with hyperuricemia.
Type: article
URI: http://hdl.handle.net/2115/76941
Appears in Collections:北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

 - Hokkaido University